Novo Nordisk is a global healthcare company with 95 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat obesity, haemophilia, growth disorders and other serious chronic diseases. Headquartered in Denmark, Novo Nordisk employs approximately 43,100 people in 79 countries and markets its products in more than 170 countries.
Business & Industry
- GSK and Vir Biotechnology announce United States government agreement to purchase additional supply of sotrovimab
- New Vaxzevria data further support its use as third dose booster
- Novartis and Molecular Partners report positive topline data from Phase 2 study for ensovibep (MP0420), a DARPin antiviral therapeutic for COVID-19
- Amgen and Arrakis Therapeutics announce multi-target collaboration to identify novel RNA degrader small molecule therapeutics
- Bayer and Mammoth Biosciences to collaborate on novel gene editing technolog
Research & Development
- WHO recommends two new drugs to treat patients with COVID-19
- Research team finds new dual benefit mode of action for a drug candidate to fight COVID-19
- COVID-19 - Omicron: resistant to most monoclonal antibodies but neutralized by a booster dose
- COVID-19 can trigger self-attacking antibodies
- Treatments in weeks, not months: Scientists develop ambitious pandemic response plan
- Scientists identify antibodies that can neutralize omicron
- Stopping dementia at the nose with combination of rifampicin and resveratrol
Conferences & Events
- New vaccine ingredient shows promise
- Modernise your Medical Affairs Insight Management with ViiV Healthcare, Eisai, ASC Therapeutics and Within3
- Novartis, Bayer and Boehringer Ingelheim to showcase their commitment to a reimagined pharma industry
- Scientists urge for investment now in highly potent vaccines to prevent the next pandemic
- CPhI Worldwide to return in 2021
- Reuters Events' Cell & Gene Therapy USA
- Total health: Build a better healthcare system
Regulatory Affairs
- FDA authorizes additional oral antiviral for treatment of COVID-19 in certain adults
- FDA authorizes first oral antiviral for treatment of COVID-19
- FDA expands eligibility for Pfizer-BioNTech COVID-19 booster dose to 16- and 17-year-olds
- FDA authorizes Pfizer-BioNTech COVID-19 vaccine for emergency use in children 5 through 11 years of age
- FDA, NIH, and 15 private organizations join forces to increase effective gene therapies for rare diseases